Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Regeneron Pharmaceuticals ... in combination with oncology drug Libtayo (cemiplimab). The study is currently enrolling patients with metastatic and locally advanced solid tumors who have exhausted ...

Although the patient population ... point, as Libtayo continues to report growth and the company’s bispecific antibodies post impressive data. Beyond Libtayo, Regeneron's oncology pipeline ...

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve ... another chronic disease with a large patient population. The company also has an extremely ...